GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cidara Therapeutics Inc (NAS:CDTX) » Definitions » Cyclically Adjusted Book per Share

Cidara Therapeutics (Cidara Therapeutics) Cyclically Adjusted Book per Share : $53.58 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Cidara Therapeutics Cyclically Adjusted Book per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Cidara Therapeutics's adjusted book value per share for the three months ended in Mar. 2024 was $-3.898. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $53.58 for the trailing ten years ended in Mar. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2024-06-09), Cidara Therapeutics's current stock price is $12.84. Cidara Therapeutics's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $53.58. Cidara Therapeutics's Cyclically Adjusted PB Ratio of today is 0.24.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Cidara Therapeutics was 0.43. The lowest was 0.21. And the median was 0.27.


Cidara Therapeutics Cyclically Adjusted Book per Share Historical Data

The historical data trend for Cidara Therapeutics's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cidara Therapeutics Cyclically Adjusted Book per Share Chart

Cidara Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - 54.15

Cidara Therapeutics Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - 54.06 54.15 53.58

Competitive Comparison of Cidara Therapeutics's Cyclically Adjusted Book per Share

For the Biotechnology subindustry, Cidara Therapeutics's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cidara Therapeutics's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cidara Therapeutics's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Cidara Therapeutics's Cyclically Adjusted PB Ratio falls into.



Cidara Therapeutics Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cidara Therapeutics's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book= Book Value per Share /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-3.898/131.7762*131.7762
=-3.898

Current CPI (Mar. 2024) = 131.7762.

Cidara Therapeutics Quarterly Data

Book Value per Share CPI Adj_Book
201406 0.000 100.560 0.000
201409 0.000 100.428 0.000
201412 -18.032 99.070 -23.985
201503 -25.976 99.621 -34.360
201506 177.749 100.684 232.640
201509 164.462 100.392 215.877
201512 150.748 99.792 199.063
201603 137.398 100.470 180.210
201606 122.022 101.688 158.127
201609 106.230 101.861 137.428
201612 105.143 101.863 136.020
201703 90.437 102.862 115.858
201706 72.670 103.349 92.659
201709 59.971 104.136 75.889
201712 58.214 104.011 73.754
201803 47.611 105.290 59.588
201806 59.352 106.317 73.565
201809 50.399 106.507 62.357
201812 42.522 105.998 52.863
201903 32.927 107.251 40.457
201906 23.746 108.070 28.955
201909 29.668 108.329 36.089
201912 22.362 108.420 27.179
202003 26.505 108.902 32.072
202006 19.682 108.767 23.846
202009 13.453 109.815 16.143
202012 4.775 109.897 5.726
202103 0.784 111.754 0.924
202106 6.379 114.631 7.333
202109 -0.467 115.734 -0.532
202112 6.358 117.630 7.123
202203 1.436 121.301 1.560
202206 -2.300 125.017 -2.424
202209 2.548 125.227 2.681
202212 -3.985 125.222 -4.194
202303 5.962 127.348 6.169
202306 3.416 128.729 3.497
202309 1.778 129.860 1.804
202312 -1.812 129.419 -1.845
202403 -3.898 131.776 -3.898

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.


Cidara Therapeutics  (NAS:CDTX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Cidara Therapeutics's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=12.84/53.58
=0.24

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of Cidara Therapeutics was 0.43. The lowest was 0.21. And the median was 0.27.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Cidara Therapeutics Cyclically Adjusted Book per Share Related Terms

Thank you for viewing the detailed overview of Cidara Therapeutics's Cyclically Adjusted Book per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Cidara Therapeutics (Cidara Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
6310 Nancy Ridge Drive, Suite 101, San Diego, CA, USA, 92121
Cidara Therapeutics Inc is a biotechnology company. It is focused on the discovery, development, and commercialization of novel anti-infectives for the treatment and prevention of diseases. The company's Rezafungin is a novel molecule in the echinocandin class of antifungals. It is developing rezafungin for the first-line treatment and prevention of serious, invasive fungal infections which are associated with high mortality rates. Its other product candidates include CD377, CD388, RSV AVC, HIV AVC, and SARS-CoV-2 AVC.
Executives
Leslie Tari officer: Chief Scientific Officer C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR SUITE 101, SAN DIEGO CA 92121
Taylor Sandison officer: Chief Medical Officer 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Jeffrey Stein director, officer: President & CEO 6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Shane Ward officer: CHIEF LEGAL OFFICER C/O VERSARTIS, INC., 4200 BOHANNON DR., SUITE 250, MENLO PARK CA 94025
Preetam Shah officer: CFO & CBO C/O BRAINSTORM CELL THERAPEUTICS, INC., 1325 AVENUE OF AMERICAS, 28TH FLR., NEW YORK NY 10019
Paul Daruwala officer: Chief Medical Officer 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Brady Johnson officer: Dir. of Finance & Controller 6310 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Timothy R Franson director 320 WAKARA WAY, SALT LAKE CITY UT 84108
Carin Canale-theakston director C/O CIDARA THERAPEUTICS, INC., 6310 NANCY RIDGE DR STE 101 CA 92121
Bonnie L Bassler director REGENERON PHARMACEUTICALS, INC., 777 OLD SAW MILL RIVER ROAD, TARRYTOWN NY 10591
James E. Levine officer: Chief Financial Officer 55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Theodore R Schroeder director 12481 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO CA 92130
Chrysa Mineo director 10835 ROAD TO THE CURE, SUITE 205, SAN DIEGO CA 92121
David L Gollaher director 6310 NANCY RIDGE DR, SAN DIEGO CA 92121
Daniel D Burgess director C/O HOLLIS-EDEN PHARMACEUTICALS, 4435 EASTGATE MALL STE.400, SAN DIEGO CA 92121

Cidara Therapeutics (Cidara Therapeutics) Headlines